Drug intelligence / Profile preview

Neofen Combo

Development stage
Unknown
Lead developer
Belupo
Modality
Small Molecules
Administration
Oral
01

Overview

Neofen Combo is a fixed-dose combination of ibuprofen (200 mg) and paracetamol (500 mg) developed by Belupo and distributed by Farmavita. It is indicated for the short-term relief of mild to moderate pain, including headache, migraine, back pain, menstrual pain, toothache, muscular pain, sore throat, and fever. The combination utilizes the synergistic effects of two distinct mechanisms of action: ibuprofen, a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes to reduce prostaglandin synthesis, and paracetamol, an analgesic and antipyretic that primarily acts on the central nervous system to inhibit prostaglandin synthesis and raise the pain threshold. This multimodal approach provides faster, stronger, and longer-lasting pain relief compared to either active ingredient alone.

Brand names
Advil Dual ActionCombiflamCombogesicMaxigesicNeofen ComboNuromol
Other names
acetaminophen + ibuprofenacetaminophen/ibuprofenibuprofen + acetaminophenibuprofen + paracetamolibuprofen/acetaminophenibuprofen/paracetamolparacetamol + ibuprofenparacetamol/ibuprofen
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on Neofen Combo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neofen Combo.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call